Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$21.10 USD

21.10
1,979,088

-0.03 (-0.14%)

Updated Sep 16, 2025 03:59 PM ET

After-Market: $21.50 +0.40 (1.90%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM

by Zacks Equity Research

Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.

Zacks Equity Research

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.

Zacks Equity Research

Abbott (ABT) Organic Growth Strong, Pediatric Nutrition Down

by Zacks Equity Research

Within Medical Device, Abbott (ABT) is facing challenging conditions in terms of procedure volume.

Zacks Equity Research

Here's Why You Should Hold On to Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on solid first-quarter results and a gradually stabilizing global musculoskeletal market.

Zacks Equity Research

Quest Diagnostics (DGX) Base Business Rebounds Amid Price Woe

by Zacks Equity Research

Contributions from acquisitions and Professional Lab Services relationships accelerate base business growth for Quest Diagnostics (DGX).

Zacks Equity Research

CVS Health (CVS) Gains From Digitalization, Hurt by Seasonality

by Zacks Equity Research

CVS Health's (CVS) consumer-centric digital strategy is now more relevant in the current environment as people are using technology while staying indoors.

Zacks Equity Research

Here's Why You Should Add Phibro (PAHC) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC) on solid third-quarter performance and potential in emerging markets.

Zacks Equity Research

Bruker's (BRKR) Research Tools Enable New insight on PACS

by Zacks Equity Research

Bruker's (BRKR) quantitative NMR and MS assay platform together with Australian National Phenome Centre evaluate risk and longitudinal monitoring of post-acute COVID-19 syndrome.

Zacks Equity Research

Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips

by Zacks Equity Research

Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.

Zacks Equity Research

Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable

by Zacks Equity Research

Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.

Zacks Equity Research

Medtronic (MDT) Reveals Promising Results From Evolut Trial

by Zacks Equity Research

The Low Risk Trial has demonstrated non-inferiority of Medtronic's (MDT) TAVR system over open heart surgery.

Zacks Equity Research

LabCorp's (LH) New Bioanalytical Lab to Boost APAC Operation

by Zacks Equity Research

The new laboratory by LabCorp (LH) is set to enable faster data turnaround for early phase trials in Asia-Pacific markets.

Zacks Equity Research

Thermo Fisher (TMO) to Boost Cell Therapies With UCSF Deal

by Zacks Equity Research

Thermo Fisher's (TMO) collaboration with UCSF will enable end-to-end solution to accelerate cell therapy development and manufacturing with new facility.

Zacks Equity Research

TeleFlex (TFX) Urolift Grows, Organic Sales Hit by Pandemic

by Zacks Equity Research

On the strength of a successful 2020 campaign, Teleflex (TFX) doubles the awareness for UroLift in the targeted population of men with BPH.

Zacks Equity Research

LabCorp's (LH) Pixel Kit Gets EUA for Younger Population

by Zacks Equity Research

LabCorp (LH) becomes the first major commercial laboratory to offer a COVID-19 PCR Test Home Collection Kit for children and adolescents.

Zacks Equity Research

Abbott (ABT) Receives CE Mark for Latest Navitor TAVI System

by Zacks Equity Research

Abbott's (ABT) latest-generation Navitor TAVI system features improvements to reduce or eliminate a backflow of blood around valve implants.

Zacks Equity Research

Here's Why You Should Buy Henry Schein (HSIC) Stock Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) on solid first-quarter performance and strategic deals.

Zacks Equity Research

Medtronic's (MDT) Coronary Market Share Grows Amid Pandemic

by Zacks Equity Research

In Gastrointestinal, Medtronic (MDT) is witnessing some modest share gains, driven in part by its partnership with the NHS in England.

Zacks Equity Research

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) on strong quarterly results and robust pump sales.

Zacks Equity Research

Tandem (TNDM) Global Growth Strong, Costs Continue to Rise

by Zacks Equity Research

Tandem Diabetes (TNDM) is witnessing high international demand for the t:slim X2 pump.

Zacks Equity Research

Here's Why You Should Buy Amedisys (AMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Amedisys (AMED) on bright Personal Care prospects, and strategic acquisitions and partnerships.

Zacks Equity Research

Here's Why You Should Buy Boston Scientific (BSX) Stock Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) owing to its solid first-quarter performance and impressive value-added acquisitions.

Zacks Equity Research

New Strong Buy Stocks for May 7th

by Zacks Equity Research

CBT, OMI, ARCB, BWFG, and NVST have been added to the Zacks Rank #1 (Strong Buy) List on May 7, 2021.

Zacks Equity Research

Envista (NVST) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 74.19% and 11.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Investors Need to Take Advantage of the Zacks ESP Screener

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.